Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results

Seres Therapeutics (NASDAQ:MCRB) posted its earnings results on Thursday. The biotechnology company reported ($1.76) EPS for the quarter, topping analysts’ consensus estimates of ($2.39) by $0.63, FiscalAI reports. The firm had revenue of $0.44 million for the quarter.

Seres Therapeutics Stock Performance

Seres Therapeutics stock traded down $0.13 during trading hours on Thursday, reaching $8.80. 7,612 shares of the stock were exchanged, compared to its average volume of 70,235. Seres Therapeutics has a 52-week low of $6.53 and a 52-week high of $29.98. The stock has a market cap of $79.64 million, a P/E ratio of -2.46 and a beta of 0.31. The firm’s 50 day moving average is $12.59 and its 200 day moving average is $15.92.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Seres Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares in the last quarter. Invesco Ltd. boosted its holdings in Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 3,918 shares in the last quarter. State Street Corp increased its position in Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 4,170 shares during the period. Vontobel Holding Ltd. increased its position in Seres Therapeutics by 4.8% during the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after purchasing an additional 4,723 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MCRB shares. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $14.33.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.